 33item 7managements discussion and analysis of financial condition and results of operations 34item 7aquantitative and qualitative disclosures about market risk 57item 8financial statements and supplementary data 59item 9changes in and disagreements with accountants on accounting and financial disclosure 121item 9acontrols and procedures 121item 9bother information 121   part iii  122item 10directors executive officers and corporate governance 122item 11executive compensation 122item 12security ownership of certain beneficial owners and management and related stockholder matters 122item 13certain relationships and related transactions and director independence 122item 14principal accountant fees and services 122   part iv  122item 15exhibits and financial statement schedules 123   signatures 131   2part iitem 1 businessthe companyboston scientific corporation is a worldwide developer manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties our mission is to transform lives through innovative medical solutions that improve the health of patients around the world when used in this report the terms we us our and the company mean boston scientific corporation and its divisions and subsidiariesour history began in the late 1960s when our cofounder john abele acquired an equity interest in meditech inc a research and development company focused on developing alternatives to surgery in 1969 meditech introduced a family of steerable catheters used in some of the first lessinvasive procedures performed in 1979 john abele joined with pete nicholas to form boston scientific corporation which indirectly acquired meditech this acquisition began a period of active and focused new product development innovation market development and organizational growth since then we have advanced the practice of lessinvasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the bodyour net sales have increased substantially since our formation our growth has been fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry and to build depth of portfolio within our focus businesses our strategic acquisitions have helped us to add promising new technologies to our pipeline and to offer one of the broadest product portfolios in the world for use in lessinvasive procedures in our target areas of cardiovascular rhythm management and medical surgical we believe that the depth and breadth of our product portfolio has also enabled us to compete more effectively in the current healthcare environment that seeks to improve outcomes and lower costs our strategy of category leadership also enables us to compete in a changing contracting landscape and position our products with physicians managed care large buying groups governments and consolidation among hospitals while also expanding internationally and managing the complexities of the global healthcare marketbusiness strategywe operate following five strategic imperatives strengthen execution to grow share expand into high growth adjacencies drive global expansion fund the journey to fuel growth and develop key capabilities we believe that our execution of these strategic imperatives will drive innovation accelerate profitable revenue growth and increase stockholder value our approach to innovation combines internallydeveloped products and technologies with those we may obtain externally through strategic acquisitions and alliances our research and development efforts are focused largely on the development of nextgeneration and novel technology offerings across multiple programs and divisions in addition we have undertaken several strategic acquisitions to help us to continue to be a leader in the medical device industry we expect to continue to invest in our core franchises and also investigate opportunities to further expand our presence in and diversify into strategic growth adjacencies and new global markets during the last several years we have completed multiple acquisitions to strengthen our core franchises and expand into high growth adjacencies and global markets to support the achievement of our strategic and organizational objectives we have an enterprise risk management program that coordinates a consolidated view of the key risks inherent in achieving our business strategies so we can anticipate and adapt to potential challenges to preserve and grow shareholder value our board of directors oversees risk management and focuses on the most significant risks facing the company including strategic operational financial and legal and compliance risksproductsduring 2016 our products were offered for sale by seven core businesses interventional cardiology cardiac rhythm management endoscopy peripheral interventions urology and pelvic health neuromodulation and electrophysiology during 2016 we derived 27 percent of our sales from our interventional cardiology business 22 percent of our sales from our cardiac rhythm management business 17 percent of our sales from our endoscopy business 12 percent of our sales from our peripheral interventions business 12 percent of our sales from our urology and pelvic health business seven percent of our sales from our neuromodulation business and three percent of our sales from our electrophysiology businessthe following section describes certain of our product offerings in addition see 